Healthcare Software Firm Waystar Contemplates Sale Amid Market Challenges
Waystar considers strategic options, including a potential sale, after a 24% stock slump this year.
Waystar, a healthcare software company known for its payment management solutions, is exploring strategic options, including a potential sale, according to multiple sources familiar with the situation. This development comes just two years after the company's stock market debut in New York. The Lehi, Utah, and Louisville, Kentucky-based firm has reportedly engaged investment bank Evercore to oversee the process, which remains in its preliminary stages.
Potential Shift in Ownership
The exploration of a sale could signal a significant shift for Waystar, which was formed from the 2017 merger of healthcare revenue management firms Zirmed and Navicure. The company's biggest investors include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT currently holds a 13% stake, while CPPIB owns 10%, and BlackRock Institutional Trust Company has an 8% stake, according to data from LSEG.
Despite the interest in exploring a sale, sources caution that plans are not yet finalized and could change. A sale might not materialize, they noted, given the current market conditions and investor sentiment.
Market Challenges and Valuation
Waystar's market value has declined to approximately $4.8 billion following a 24% drop in its share price this year. This decrease is part of a broader downturn affecting the software sector. Initially, Waystar positioned itself as a technology company, aiming for higher valuations that tech firms typically enjoy. However, concerns over potential disruptions from advancements in artificial intelligence have put pressure on the company's stock, as highlighted in a Morgan Stanley report from July.
Waystar's shares had previously seen a rise from $20 to a peak of $45 in 2025, driven by investor enthusiasm for its tech-focused strategy. However, the current market environment has prompted a reevaluation of its position and potential strategic moves.
Advisory and Stakeholder Responses
Neither Waystar nor Evercore have commented on the ongoing discussions. EQT and BlackRock have also declined to comment, while CPPIB has yet to respond to inquiries. The exploration of a sale could help gauge whether investor appetite for software companies is recovering, despite the recent challenges faced by the sector.
The outcome of this strategic review remains uncertain, but Waystar's decision to consider selling highlights the pressures and opportunities present in the healthcare technology market. As the company navigates these challenges, its future direction will likely be closely watched by stakeholders and industry observers alike.